UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 49

of 'Prognostic and predictive factors in early, nonmetastatic breast cancer'

49
TI
Revision of the American Joint Committee on Cancer staging system for breast cancer.
AU
Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL
SO
J Clin Oncol. 2002;20(17):3628.
 
PURPOSE: To revise the American Joint Committee on Cancer staging system for breast carcinoma.
MATERIALS AND METHODS: A Breast Task Force submitted recommended changes and additions to the existing staging system that were (1) evidence-based and/or consistent with widespread clinical consensus about appropriate diagnostic and treatment standards and (2) useful for the uniform accrual of outcome information in national databases.
RESULTS: Major changes included the following: size-based discrimination between micrometastases and isolated tumor cells; identifiers to indicate usage of innovative technical approaches; classification of lymph node status by number of involved axillary lymph nodes; and new classifications for metastasis to the infraclavicular, internal mammary, and supraclavicular lymph nodes.
CONCLUSION: This revised staging system will be officially adopted for use in tumor registries in January 2003.
AD
University of Texas M.D. Anderson Cancer Center and Baylor College of Medicine, Houston, TX, USA. esinglet@mdanderson.org
PMID